These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3109917)

  • 1. 89Sr radionuclide therapy: dosimetry and haematological toxicity in two patients with metastasising prostatic carcinoma.
    Blake GM; Zivanovic MA; McEwan AJ; Batty VB; Ackery DM
    Eur J Nucl Med; 1987; 13(1):41-6. PubMed ID: 3109917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases.
    Blake GM; Zivanovic MA; Blaquiere RM; Fine DR; McEwan AJ; Ackery DM
    J Nucl Med; 1988 Apr; 29(4):549-57. PubMed ID: 3351609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma.
    Breen SL; Powe JE; Porter AT
    J Nucl Med; 1992 Jul; 33(7):1316-23. PubMed ID: 1613572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurements of the strontium plasma clearance rate in patients receiving 89Sr radionuclide therapy.
    Blake GM; Zivanovic MA; Lewington VJ
    Eur J Nucl Med; 1989; 15(12):780-3. PubMed ID: 2516486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strontium kinetics in metastasized prostatic carcinoma: a comparison with the predictions of impulse response function analysis.
    Blake GM; Zivanovic MA; Gray JM
    Nucl Med Commun; 1987 Nov; 8(11):909-19. PubMed ID: 3441327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of human biokinetics of strontium on internal ingestion dose of 90Sr and absorbed dose of 89Sr to organs and metastases.
    Li WB; Höllriegl V; Roth P; Oeh U
    Radiat Environ Biophys; 2008 Apr; 47(2):225-39. PubMed ID: 18204850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strontium 89 therapy for the palliation of pain due to osseous metastases.
    Robinson RG; Preston DF; Schiefelbein M; Baxter KG
    JAMA; 1995 Aug; 274(5):420-4. PubMed ID: 7542352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strontium-89 therapy: strontium kinetics and dosimetry in two patients treated for metastasising osteosarcoma.
    Blake GM; Zivanovic MA; McEwan AJ; Condon BR; Ackery DM
    Br J Radiol; 1987 Mar; 60(711):253-9. PubMed ID: 3471288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone pain palliation with 85Sr therapy.
    Giammarile F; Mognetti T; Blondet C; Desuzinges C; Chauvot P
    J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 89Sr therapy: strontium plasma clearance in disseminated prostatic carcinoma.
    Blake GM; Wood JF; Wood PJ; Zivanovic MA; Lewington VJ
    Eur J Nucl Med; 1989; 15(1):49-54. PubMed ID: 2537216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strontium-89 radionuclide therapy: a dosimetric study using impulse response function analysis.
    Blake GM; Gray JM; Zivanovic MA; McEwan AJ; Fleming JS; Ackery DM
    Br J Radiol; 1987 Jul; 60(715):685-92. PubMed ID: 3620827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
    Brundage MD; Crook JM; Lukka H
    Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ESR dosimetry of 89Sr and 153Sm in bone.
    Kinoshita A; Braga FJ; Graeff CF; Baffa O
    Appl Radiat Isot; 2001 Feb; 54(2):269-74. PubMed ID: 11200888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
    Nair N
    J Nucl Med; 1999 Feb; 40(2):256-61. PubMed ID: 10025832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling of internal dose distributions during SR-89 treatment of a patient with bone metastases.
    Bialkowski MM; Wierzbicki JG; Porter AT
    Cancer Biother Radiopharm; 1997 Oct; 12(5):355-62. PubMed ID: 10851487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disseminated intravascular coagulation in a patient treated with strontium-89 for metastatic carcinoma of the prostate.
    Paszkowski AL; Hewitt DJ; Taylor A
    Clin Nucl Med; 1999 Nov; 24(11):852-4. PubMed ID: 10551466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer.
    Pons F; Herranz R; Garcia A; Vidal-Sicart S; Conill C; Grau JJ; Alcover J; Fuster D; Setoain J
    Eur J Nucl Med; 1997 Oct; 24(10):1210-4. PubMed ID: 9323260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective accumulation of strontium-89 in metastatic deposits in bone: radio-histological correlation.
    Ben-Josef E; Lucas DR; Vasan S; Porter AT
    Nucl Med Commun; 1995 Jun; 16(6):457-63. PubMed ID: 7545802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer].
    Haesner M; Buchali K; Pink V; Lips H
    Nuklearmedizin; 1992 Mar; 31(2):48-52. PubMed ID: 1373485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum PICP as a bone formation marker in 89Sr and external beam radiotherapy of prostatic bony metastases.
    Papatheofanis FJ
    Br J Radiol; 1997 Jun; 70(834):594-8. PubMed ID: 9227252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.